Chemistry:BC-LI-0186
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H27N3O4S |
| Molar mass | 429.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BC-LI-0186 is a compound that acts as an inhibitor of the GTPase enzyme leucyl-tRNA synthetase (LRS). This enzyme acts as part of the mTOR complex and acts as a leucine sensor which stimulates mTORC1 in the presence of leucine. BC-LI-0186 blocks the docking site for mTORC1 and thereby prevents the mTOR activation and increased protein synthesis which is usually triggered by branched-chain amino acids such as leucine, yet without inhibiting the separate catalytic activity of LRS.[1] This may have potential applications in the treatment of cancer,[2] and BC-LI-0186 has also been shown to promote muscle regeneration after injury.[3]
References
- ↑ "Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction". Nature Communications 8 (1): 732. September 2017. doi:10.1038/s41467-017-00785-0. PMID 28963468. Bibcode: 2017NatCo...8..732K.
- ↑ "Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer". Therapeutic Advances in Medical Oncology 11: 1758835919846798. 2019. doi:10.1177/1758835919846798. PMID 31205503.
- ↑ "Nontranslational function of leucyl-tRNA synthetase regulates myogenic differentiation and skeletal muscle regeneration". The Journal of Clinical Investigation 129 (5): 2088–2093. April 2019. doi:10.1172/JCI122560. PMID 30985292.
 |  |
